| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Leveraging Genpact's data, technology and AI expertise to future-proof STADA's finance organization and drive competitive advantages
NEW YORK, Sept. 12, 2024 /PRNewswire/ -- Genpact (NYSE:G), a global professional services and solutions firm delivering outcomes that shape the future, and STADA (SAZ.DE), a leading manufacturer of consumer healthcare, generic and specialty pharma medicines, today announced the renewal of a multi-year partnership. The new chapter of innovation is aimed at further derisking, scaling, and simplifying STADA's finance operations to drive competitive advantages.
Posted In: G
